(Q37725147)

22 August 2017

1 reference

title

Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making (English)

1 reference

22 August 2017

0 references

1 reference

2

Gary Remington

1 reference

22 August 2017

1

George Foussias

1 reference

PubMed ID

20370961

22 August 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

Canadian Journal of Psychiatry

22 August 2017

1 reference

22 August 2017

55

1 reference

22 August 2017

3

1 reference

22 August 2017

117-125

1 reference

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

22 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F070674371005500302

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005500302

New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005500302

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005500302

Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005500302

Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005500302

A randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005500302

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005500302

Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005500302

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005500302

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005500302

Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005500302

Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005500302

Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005500302

Extrapyramidal side-effects of antipsychotics in a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005500302

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005500302

Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005500302

Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005500302

Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005500302

The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005500302

Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005500302

Clozapine maintenance therapy in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005500302

A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674371005500302

10.1177/070674371005500302

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20370961